MBMarina Badenes

Marina Badenes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marina Badenes has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ADAM17 pathway promotes canine mammary tumor cell migration

    by André Luz, Joana Santos, José Catarino, Catarina Sousa, Joana Fonseca, Sónia Campos, Margarida Alves, Pedro V. Baptista, Pedro Faísca, Alexandra R Fernandes, et al.

    Background: ADAM17, also known as tumor necrosis factor-converting enzyme (TACE), is a pleiotropic protease that contributes to inflammation and cancer progression by activating epidermal growth factor receptor (EGFR) signaling and IL-6 trans-signaling, among other pathways. Because ADAM17 signaling remains poorly characterized in veterinary pathophysiology, we investigated its biological roles in canine mammary tumors (CMTs), one of the most common cancers in dogs, where treatment options remain limited. Methods: ADAM17 mRNA levels were compared between canine mammary carcinoma tissues and normal mammary glands. We also investigated the effects of pharmacological stimulation and/or inhibition of the ADAM17 pathway on key cancer-related biological processes in the FR37-CMT and the FR10-CMT cell lines. Specifically, we assessed cell viability and apoptosis under basal conditions and following doxorubicin treatment. In addition, we examined the impact of ADAM17 pathway modulation on epithelial-to-mesenchymal transition (EMT) and cell motility. Results: ADAM17 mRNA expression was significantly upregulated in canine mammary carcinoma tissues with grade II or more compared with normal controls, and its expression may be associated with tumor progression and dissemination. ADAM17 did not appear to play a major role in FR37-CMT cell viability, apoptosis, doxorubicin-mediated cytotoxicity, or EMT. However, ADAM17 was found to promote FR37-CMT and FR10-CMT cell motility. Conclusions: These findings suggest that pharmacological inhibition of ADAM17 activity may represent a promising strategy to limit the metastatic spread of mammary cancer in dogs.

  • Open Access

    ADAM17 and its proteolytic targets in disease pathogenesis

    by Abdulbasit Amin, Marina Badenes

    ADAM17, from the disintegrin and metalloproteinase (ADAM) family, also called tumor necrosis factor converting enzyme (TACE), is a pleiotropic protease with more than 90 substrates, including growth factors, cytokines, receptors, and adhesion molecules. The biology of ADAM17 has been extensively studied, mainly as a regulator of epidermal growth factor receptor (EGFR) and tumor necrosis factor (TNF) signaling pathways, which are crucial for growth and inflammation, respectively. Consequently, this protease has been considered a major target to treat human cancers and inflammatory disorders. Moreover, it is involved in the pathobiology of numerous other disease types. This review summarizes the current understanding of ADAM17 and the involvement of its targets in inflammation, cancer, and cardiovascular and metabolic diseases.

  • Open Access

    Epidermal growth factor receptor pathway in central nervous system regenerative medicine: a narrative review

    by Marina Badenes

    The epidermal growth factor receptor (signaling pathway is involved in numerous important mammal cell functions, such as growth, survival, proliferation, and differentiation. Associated with this, it is involved in tissue normal development and growth, tumorigenesis, and in tissue repair. Epidermal growth factor receptor is broadly expressed in the organism, including in the central and peripheral nervous system, where it has important neurotrophic functions. The central nervous system has a limited capacity for regeneration upon lesion, leading to severe disabilities, such as blindness, sensorimotor deficits, and paralysis. However, observations suggest that its innate neurogenic response may be amplified to promote the replenishment of damaged neuronal populations. In addition, the environment can also be modulated to promote regeneration. Therefore, the pathways involved in neural tissue repair have been investigated in terms of regenerative medicine, to discover new therapies to recover from traumatic injury or ischemia in the central nervous system or to inhibit the progression of neurodegenerative diseases. Growth factors have been widely accepted as the most important promoters of proliferation and neurogenesis under physiologic conditions and after injury. In this review, we summarize how the epidermal growth factor receptor signaling pathway is involved in neuronal damage and neurodegeneration in several settings, including in the olfactory epithelium, brain, spinal cord, and optic nerve, where this pathway can be modulated in the context of regenerative medicine to promote neuronal regeneration and, therefore, neurological function reestablishment in response to insults.


  • Can the HB‐EGF/EGFR pathway restore injured neurons?

    by Colin Adrain, Marina Badenes

    Heparin‐binding epidermal growth factor‐like growth factor (HB‐EGF) is a transmembrane protein that, when cleaved by metalloproteases through a process called ectodomain shedding, binds to the EGF receptor (EGFR), activating downstream signaling. The HB‐EGF/EGFR pathway is crucial in development and is involved in numerous pathophysiological processes. In this issue of The FEBS Journal, Sireci et al. reveal a previously unexplored function of the HB‐EGF/EGFR pathway in promoting neuronal progenitor proliferation and sensory neuron regeneration in the zebrafish olfactory epithelium in response to injury.


  • Open Access

    RHBDL4-triggered downregulation of COPII adaptor protein TMED7 suppresses TLR4-mediated inflammatory signaling

    by Julia D. Knopf, Susanne S. Steigleder, Friederike Korn, Nathalie Kühnle, Marina Badenes, Marina Tauber, Sebastian J. Theobald, Jan Rybniker, Colin Adrain, Marius K. Lemberg

    The toll-like receptor 4 (TLR4) is a central regulator of innate immunity that primarily recognizes bacterial lipopolysaccharide cell wall constituents to trigger cytokine secretion. We identify the intramembrane protease RHBDL4 as a negative regulator of TLR4 signaling. We show that RHBDL4 triggers degradation of TLR4’s trafficking factor TMED7. This counteracts TLR4 transport to the cell surface. Notably, TLR4 activation mediates transcriptional upregulation of RHBDL4 thereby inducing a negative feedback loop to reduce TLR4 trafficking to the plasma membrane. This secretory cargo tuning mechanism prevents the over-activation of TLR4-dependent signaling in an in vitro Mycobacterium tuberculosis macrophage infection model and consequently alleviates septic shock in a mouse model. A hypomorphic RHBDL4 mutation linked to Kawasaki syndrome, an ill-defined inflammatory disorder in children, further supports the pathophysiological relevance of our findings. In this work, we identify an RHBDL4-mediated axis that acts as a rheostat to prevent over-activation of the TLR4 pathway.


  • 2023 CBIOS Scientific Seminars - Book of Abstracts

    by Catarina Rosado, Luís Monteiro Rodrigues, Bernardo Palma, Miguel Remondes, Marina Badenes, Ângela Afonso, Constantinos Athanassopoulos, Catarina Leite, Cíntia Pêgo, Vera Isca, et al.

  • Open Access

    The ADAM17 sheddase complex regulator iTAP/Frmd8 modulates inflammation and tumor growth

    by Marina Badenes, Emma Burbridge, Ioanna Oikonomidi, Abdulbasit Amin, Érika de Carvalho, Lindsay Kosack, Camila Mariano, Pedro Domingos, Pedro Faísca, Colin Adrain

    The metalloprotease ADAM17 is a sheddase of key molecules, including TNF and epidermal growth factor receptor ligands. ADAM17 exists within an assemblage, the “sheddase complex,” containing a rhomboid pseudoprotease (iRhom1 or iRhom2). iRhoms control multiple aspects of ADAM17 biology. The FERM domain–containing protein iTAP/Frmd8 is an iRhom-binding protein that prevents the precocious shunting of ADAM17 and iRhom2 to lysosomes and their consequent degradation. As pathophysiological role(s) of iTAP/Frmd8 have not been addressed, we characterized the impact of iTAP/Frmd8 loss on ADAM17-associated phenotypes in mice. We show that iTAP/Frmd8 KO mice exhibit defects in inflammatory and intestinal epithelial barrier repair functions, but not the collateral defects associated with global ADAM17 loss. Furthermore, we show that iTAP/Frmd8 regulates cancer cell growth in a cell-autonomous manner and by modulating the tumor microenvironment. Our work suggests that pharmacological intervention at the level of iTAP/Frmd8 may be beneficial to target ADAM17 activity in specific compartments during chronic inflammatory diseases or cancer, while avoiding the collateral impact on the vital functions associated with the widespread inhibition of ADAM17.


  • Open Access

    Crosstalk between metabolism and immunity: the 3rd Annual Research Symposium of Instituto Gulbenkian de Ciencia

    by Abdulbasit Amin, Ana Neves‐Costa, Dora Pedroso, Henrique Colaço, Inês Coelho, Inês Mahú, Marina Badenes, Nádia Duarte

    The 'Crosstalks of immunity and metabolism' Symposium was focused on how the intercommunication between different organs and the immune system affects organismal health. At this meeting, experts in immunology and metabolic research provided novel insights into the growing field of immunometabolism. This report attempts to review and integrate views, ideas, propositions, and conclusions that emanated from the symposium.

  • Open Access

    Deletion of iRhom2 protects against diet-induced obesity by increasing thermogenesis

    by Marina Badenes, Abdulbasit Amin, Ismael González-García, Inês Félix, Emma Burbridge, Miguel Cavadas, Francisco José Ortega, Érika de Carvalho, Pedro Faísca, Stefania Carobbio, et al.


  • iRhom2 and TNF: Partners or enemies?

    by Marina Badenes, Colin Adrain

    IRhom2 inhibits proinflammatory signaling that stimulates liver fibrosis (Sundaram et al. , in 29 October 2019 issue).